Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Bosco who wrote (882)	4/25/2000 8:05:00 AM
From: Bosco	Read Replies (1) \| Respond to of 1298

Hi all - earning release biz.yahoo.com to me, a mixed bag. As we know, the sale of ABGX shares has given a substantial number to CEGE bottomline. Also, there is also revenues coming in from milestone payment, but it is lower YtoY. Since this too can be excluded from operating revenue in the real sense, I deem this a mild -ve. No big deal. It seems that CEGE is still on track with GVAX prostate cancer vaccine and has even initiated lung cancer vaccine [multicenter] clinical trials, I am positively encouraged. Also, her adeno-associated viral (AAV) and lentiviral gene delivery technologies should continue to be a wild card when hemopilia gene therapy gathers steam. Starting Phase I should really gain a lot of buzz. Technically, CEGE seems to has good support at this level. Unfortunately, I ve overweighed CEGE already, so I ve decided not to add position here. best, Bosco